3D PHARM X CHANGE

DEVELOPMENT OF SMALL MOLECULES: FROM CLINICAL CANDIDATE SELECTION TO TAILORED DRUG DEVELOPMENT SUPPORT

At 3D-PharmXchange, we understand the complex journey biotech and pharmaceutical companies face in developing safe, effective, and compliant small molecule therapeutics. With our broad in-house expertise and a strong industry network, we provide strategic and hands-on support tailored to your development needs.

Why choose 3D-PharmXchange?

Full development support	Knowledge transfer	Flexible deployment	Vast industrial network
Strategic & operational	Direct access to highly experienced consultants	Cost & time effective	Effective negotiations with CROs & CDMOs
Accelerate development & improve efficiency	Experts in a wide range of therapeutics & indications	To meet the timeline, budget & quality requirements	Due diligence, valuation, and venture capture

Our Expertise in Drug Development

	CMC	Non-Clinical	Clinical	Regulatory Affairs
Scope of services	Assist with early development to commercial manufacturing	Translational, (GLP-) toxicology, ADME, dose selection	Clinical science and operations, medical writing and project management	Preparation and submission of IND/CTA & registration file (NDA/BLA/MAA)
Expert guidance	DS & DP Process development, CDMO selection & management, GMP, Quality (QA/QP) QMS, CMC RA	CRO selection & monitoring, data analysis, biomarker selection & development, combination therapies	Clinical CRO selection, documentation, statistical support, Clinical study support incl. platform clinical trials	Regulatory strategy, Scientific advice, Paediatric investigational plan, orphan drug designation

65+	32	15	25+	300+
projects ongoing	small molecule projects	years track record	FTE (in-house)	projects completed

Maidstone 48a, 5026SK, Tilburg, NL W 3d-pxc.com E info@3d-pxc.com T +31 (0)13 534 8272

Your clinical roadmap to success



We offer end-to-end support across the entire small molecule development lifecycle, from preclinical stages through to marketing authorization. Our services include CMC development (synthesis, formulation, and analytical development), CDMO selection and oversight, clinical trial supply coordination, regulatory affairs (RA), quality assurance (QA), and non-clinical development, including toxicology and pharmacology. We take a multidisciplinary approach to de-risk projects and accelerate development, ensuring an efficient and streamlined process.

Our small molecules track record



Analgesics, CNS agents, immuno-oncology



Peptides, peptidomimetics & siRNA/ASO

ADC linker payloads

Repurposed drugs

Theranostics (^{18}F, ^{225}Ac, ^{177}Lu)

Small molecule development brings its own set of challenges from optimizing lead compounds and navigating regulatory pathways to ensuring scalable manufacturing and quality compliance. Our experienced team helps you anticipate and overcome these challenges to keep your development on track.

From gap analysis to multidisciplinary support

At 3D-PharmXchange, we help biotech companies grow from concept to launch with a tailored approach that fits your unique development needs. Whether you need to identify strategic gaps, targeted expertise, or fully integrated development support, we offer flexible collaboration in three tiers:

Review of data
Outline pre-clinical strategy
Review / recommend CROs

Gap Analysis

CMC & Quality
Non-clinical
Clinical
Regulatory Affairs
Project Management

Discipline-specific support

Gap analysis
Non-clinical safety & ADME
CRO management
DS/DP & formulation development
CDMO management
FiH clinical protocol outline
Target product profile
Regulatory Strategy
Project leadership

Integrated Development

Ready to accelerate your small molecule drug development?
Reach out to 3D-PharmXchange to discuss your needs.

Maidstone 48a, 5026SK, Tilburg, NL
W 3d-pxc.com
E info@3d-pxc.com
T +31 (0)13 534 8272